In vitro immunogenic and immunostimulatory effects of zwitterionized 23-valent pneumococcal polysaccharide vaccine compared with nonzwitterionized vaccine

Current Therapeutic Research - Clinical and Experimental

Volumn 71, Issue 1, 2010, Pages 60-77

  Abdulamir, Ahmed S ^a,b   Hafidh, Rand R ^a,c   Abubaker, Fatimah ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b AL NAHRAIN UNIVERSITY   (Iraq)

^c UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

cancer; immune suppression; immunostimulatory; pneumo 23; polyvalent pneumococcal vaccine; zwitterionic

Indexed keywords

EID: 78650990848     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2010.02.004     Document Type: Article

References (29)

1. Pasteur Merieux Connaught. Immunodeficiency. In: Vaccine against pneumococcal infection. Bulletin, 2004, 12–14.
2. Rybachenko, VV, Sementsov, VK, Manuilov, VM, Zabolotnyi, SP, About the results of using vaccine “Pneumo-23” in Northern fleet [in Russian]. Voen Med Zh. 330 (2009), 11–13.
3. Rybachenko, VV, Sementsov, VK, Manuilov, VM, Zabolotnyi, SP, About the results of using vaccine “Pneumo-23” in Northern fleet [in Russian]. Voen Med Zh., 330, 2009, 96.
4. van der Harst, S, Two pneumococcal vaccines: The 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk [in Dutch]. Ned Tijdschr Geneeskd. 151 (2007), 1853–1854 author reply 1854.
5. Kazancioglu, R, Sever, MS, Yüksel-Onel, D, et al. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine. Clin Transplant. 14 (2000), 61–65.
6. Uslu, A, Yetis, H, Aykas, A, et al. The efficacy and immunogenicity of Pneumo-23 and ACT-HIB in patients undergoing splenectomy. Ulus Travma Acil Cerrahi Derg. 12 (2006), 277–281.
7. Gallorini, S, Berti, F, Parente, P, et al. Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J Immunol. 179 (2007), 8208–8215.
8. Cobb, BA, Kasper, DL, Zwitterionic capsular polysaccharides: The new MHCII-dependent antigens. Cell Microbiol. 7 (2005), 1398–1403.
9. Wack, A, Gallorini, S, Bacterial polysaccharides with zwitterionic charge motifs: Toll-like receptor 2 agonists, T cell antigens, or both?. Immunopharmacol Immunotoxicol. 30 (2008), 761–770.
10. Richard, JP, Amyes, TL, On the importance of being zwitterionic: Enzymatic catalysis of decar-boxylation and deprotonation of cationic carbon. Bioorg Chem. 32 (2004), 354–366.
11. Gaudy, AF, Colorimetric determination of protein and carbohydrate. Ind Water Wastes. 7 (1962), 17–22.
12. Sodhi, A, Tarang, S, Kesherwani, V, Concanavalin A induced expression of Toll-like receptors in murine peritoneal macrophages in vitro. Int Immunopharmacol. 7 (2007), 454–463.
13. Wang, J, Sun, R, Wei, H, et al. Pre-activation of T lymphocytes by low dose of concanavalin A aggravates toll-like receptor-3 ligand-induced NK cell-mediated liver injury. Int Immunopharmacol. 6 (2006), 800–807.
14. Wahlström, J, Berlin, M, Sköld, CM, et al. Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax. 54 (1999), 339–346.
15. Wigzell, H, Andersson, B, Isolation of lymphoid cells with active surface receptor sites. Annu Rev Microbiol. 25 (1971), 291–308.
16. Shimoyama, Y, Kubota, T, Watanabe, M, et al. Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. J Surg Oncol. 41 (1989), 12–18.
17. Kane, MD, Schwarz, RD, St Pierre, L, et al. Inhibitors of V-type ATPases, bafilomycin A1 and concanamycin A, protect against beta-amyloid-mediated effects on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem. 72 (1999), 1939–1947.
18. Schuurs, AH, Van Weeman, BK, Enzyme-immunoassay. Clin Chem Acta. 31 (1977), 1–40.
19. Taylor, RB, Duffus, PH, Raff, MC, de Petris, S, Redistribution and pinocytosis of lymphocyte surface immunoglobulin molecules induced by anti-immunoglobulin. Nat New Biol. 12 (1970), 225–229.
20. Ben Trivedi, A, Kitabatake, N, Doi, E, Toxicity of dimethyl sulfoxide as a solvent in bioassay system with HeLa cells evaluated colorimetrically with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide. Agric Biol Chem. 54 (1990), 2961–2966.
21. Kalinski, P, Nakamura, Y, Watchmaker, P, et al. Helper roles of NK CD8+ T cells in the induction of tumor immunity,.Polarized dendritic cells as cancer vaccines. Immunol Res. 36 (2006), 137–146.
22. Knutson, KL, Disis, ML, Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer lmmunol lmmunother. 54 (2005), 721–728.
23. Iwatsuki, K, Yamamoto, T, Tsuji, K, et al. A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Acta Med Okayama. 58 (2004), 169–180.
24. Markelova, EV, Gushchina, IaS, Kostinov, MP, Zhuravleva, NV, Clinical and immunological effect produced by vaccination with “Pneumo 23” of children with atopic bronchial asthma [in Russian]. Zh Mikrobiol Epidemiol lmmunobiol. 4 (2005), 83–85.
25. Ryzhov, AA, Katosova, LK, Kostinov, MP, et al. Evaluation of the influence of the bacterial vaccines Pneumo-23 and Act-HIB on the course of the chronic inflammatory process of the respiratory organs in children [in Russian]. Zh Mikrobiol Epidemiol lmmunobiol, 2005, 84–87.
26. Weiner, HL, Zhang, ZJ, Khoury, SJ, et al. Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens. Ann N Y Acad Sci. 636 (1991), 227–232.
27. Berzofsky, JA, Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity. Vaccine. 6 (1988), 89–93.
28. Baeuerle, PA, Baltimore, D, NF-kappa B: Ten years after. Cell. 87 (1996), 13–20.
29. Aderem, A, Ulevitch, RJ, Toll-like receptors in the induction of the innate immune response. Nature. 406 (2000), 782–787.